At 18h, … 3.2. IFN-Gamma Promotes DC Costimulation to CD4+ T Cells Only in the Presence of TLR Ligands CD80 and CD86 which both bind CD28 and CTLA-4 on the surface of T cells providing regulatory signals leading to T cell activation are two of several cell surface molecules involved in T cell costimulation. Given the GDC-0449 price ability of IFN-gamma to upregulate surface expression of CD80 and CD86 on DC, we next investigated the capacity of these cells to promote T cell costimulation resulting in proliferation. Day 5 bone marrow-derived DCs were pretreated

with IFN-gamma and TLR ligands, LPS, or zymosan and then assessed for their ability to co-stimulate proliferation of CD4+ T cells in the Inhibitors,research,lifescience,medical presence of immobilized anti-CD3 antibody (Figure 3). IFN-gamma-treated DCs alone were unable to induce CD4+ T cell proliferation, in line with the low levels of CD80 and CD86 expression observed on these cells (Figures ​(Figures11 and ​and3).3). However, Inhibitors,research,lifescience,medical in the presence of TLR ligands, IFN-gamma-treated DC promoted a high level of

CD4+ T cell proliferation, peaking at day 5. At this time point, the correlation between DC number and CD4+ T cell proliferation was assessed, with a positive trend between DC number and CD4+ T cell proliferation observed (Figure 3). Figure 3 IFN-gamma Inhibitors,research,lifescience,medical enhances DC costimulation only when the TLR ligand is present. Days 4-5 bone marrow cultures preconditioned with IFN-gamma (black symbols) or no IFN-gamma (open symbols) for 2h was stimulated with LPS (TLR4 ligand) or zymosan (TLR2 … 3.3. IFN-Gamma Enhances Antigen-Specific CD4+ T Cell Response Only Inhibitors,research,lifescience,medical in the Presence of TLR Ligands The ability of IFN-gamma to potentiate antigen specific CD4+ T cell proliferation was investigated. DCs were incubated with IFN-gamma and pulsed with the model antigen ovalbumin (OVA) and then incubated with CD4+ transgenic T cells from OT-II mice which carry a Inhibitors,research,lifescience,medical transgenic CD4 T cell receptor specific for the MHC class II restricted OVA peptide,

OVA323–339 [38]. The ability of the DC to induce proliferation of the OT-II CD4+ T cells in the presence and absence of TLR ligation was monitored from days 1–5 (Figure 4). Interestingly, the presence of TLR ligands alone induced CD4+ T cell proliferation to OVA very poorly. However, IFN-gamma pre-treatment Rolziracetam dramatically enhanced antigen presentation by DCs, as evident with the high levels of CD4+ T cell proliferation. At the peak day of proliferation, day 3, the effect of DC number on proliferative responses was examined, with results again demonstrating a positive correlation between DC number and the magnitude of CD4+ T cell proliferation. Figure 4 IFN-gamma enhances DC antigen presentation via MHC-class II, only in the presence of a TLR stimulus. Day 4 bone marrow cultures preconditioned with IFN-gamma for 2h were pulsed with OVA in the presence of LPS (TLR4 ligand) or zymosan (TLR2 ligand) … 4.